← Ablatotech Signals
Oncology SignalsArticle

A putative therapeutic target in non-small cell lung cancer: Q9BY67

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
November 19, 2026 · Lead editor: OncologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — Q9BY67 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in non-small cell lung cancer.

Background

The putative target UniProt:Q9BY67 has been identified as a candidate of interest in non-small cell lung cancer (NSCLC), a disease characterized by significant molecular heterogeneity and therapeutic challenges. NSCLC remains a leading cause of cancer mortality, and the discovery of novel molecular targets is critical to advancing personalized treatment strategies. Although Q9BY67 has appeared in gene expression profiling studies related to NSCLC, it currently lacks representation in clinical development programs, suggesting an opportunity for further investigation.

Data-mining rationale

This candidate emerged from a systematic cross-referencing of reviewed human protein entries in UniProt annotated for NSCLC against a comprehensive collection of 497 microarray datasets from the NCBI Gene Expression Omnibus (GEO). Several datasets (GDS:200346526, GDS:200305086, GDS:200246303, GDS:200298765, GDS:200235829) showed expression signals involving Q9BY67 in NSCLC samples. These transcriptomic data provide a valuable resource for hypothesis generation by linking protein-level annotations with gene expression patterns in tumor contexts. This integrative approach supports prioritizing Q9BY67 as a putative target warranting further experimental validation.

Why prior analyses may have missed this

Many of the GEO datasets underlying this candidate’s identification were generated before the adoption of modern empirical-Bayes statistical methods such as limma, which incorporate rigorous multiple-testing corrections like the Benjamini-Hochberg false discovery rate (FDR). Earlier analyses may have used less robust statistical techniques, increasing the risk of false positives or negatives and potentially obscuring true differential expression signals. Consequently, the relevance of Q9BY67 in NSCLC may have been underrecognized or overlooked due to methodological limitations in data analysis and interpretation.

Reasoning for further validation

To clarify the putative role of Q9BY67 in NSCLC, several validation steps are recommended. First, re-analysis of the matched GEO datasets using limma with appropriate FDR control would establish the statistical robustness of differential expression findings. Subsequent experimental validation by quantitative PCR in independent NSCLC cohorts would confirm transcript-level alterations. Assessing tissue specificity through resources such as GTEx and the Human Protein Atlas would provide context regarding expression in lung tissue and tumor microenvironments. Network analyses using STRING or OmniPath could reveal pathway associations and functional interactions, offering mechanistic insights. If these investigations support Q9BY67’s involvement, evaluation of druggability via databases like DGIdb and ChEMBL would inform translational potential. These steps would help advance Q9BY67 from a computationally identified candidate to a biologically and clinically relevant target hypothesis in NSCLC.


© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications